FOLH1 and prostate carcinoma: In vitro studies demonstrated that the targeted QDs were readily taken up by PSMA-overexpressing C4-2 human prostate cancer cells, while non-targeted PEGylated QDs exhibited minimal uptake by prostate cancer cells.